Drug Profile
AB 329
Alternative Names: DS 1205; DS 1205b; DS-1205cLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer AnHeart Therapeutics; Daiichi Sankyo Company
- Class Amides; Antineoplastics; Dioxanes; Fluorobenzenes; Phenyl ethers; Pyrans; Pyridines; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Haematological malignancies; Solid tumours
- Research Ovarian cancer
- No development reported Non-small cell lung cancer
Most Recent Events
- 10 Apr 2024 AnHeart Therapeutics has been acquired by Nuvation Bio
- 05 Dec 2023 Preclinical trials in Breast cancer in USA (unspecified route) prior to December 2023
- 05 Dec 2023 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)